Dear all

consider that you have a new clinical assay to measure an antibody level in human serum that goes together with the clinical development of a new vaccine. I understand that this clinical assay should be fully validated for phase 3 clinical studies. But how about phase 1 and 2? is fit-for-purpose considered sufficient? Thanks a lot